Madrigal (MDGL) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $364.3M
- Gross margin
- 91.48%
- Net income (quarter)
- −$57.9M
- Net margin
- −25.32%
- Return on equity
- −53.31%
- EPS (trailing twelve months)
- −$13.99
- Book value per share
- $22.68
- Price to book
- 19.95
- Debt to assets
- 57.92%
Company profile
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Frequently asked questions
Is Madrigal (MDGL) profitable?
No. Madrigal reported a net loss of $325.1M over the trailing twelve months.
How much revenue does Madrigal (MDGL) make?
Madrigal generated $1.3B in revenue over the trailing twelve months, up 71.17% year over year.
How do I buy stock in Madrigal (MDGL)?
MDGL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.